15722-48-2
15722-48-2
Chemical Structure
Olsalazine
- CAS No.: 15722-48-2
- Formula:C14H10N2O6
- Molecular Weight:302.24
IUPAC Name: (E)-5,5'-(diazene-1,2-diyl)bis(2-hydroxybenzoic acid)
InChIKey: QQBDLJCYGRGAKP-FOCLMDBBSA-N
SMILES: O=C(O)C1=C(O)C=CC(/N=N/C2=CC(C(O)=O)=C(O)C=C2)=C1
Biological Activity: Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Olsalazine | 99.83% | Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Olsalazine (Standard) | ≥98% | Olsalazine (Standard) is an orally active prodrug of 5-ASA (HY-15027). Olsalazine (Standard) can inhibit cells proliferation and induce apoptosis. Olsalazine (Standard) can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine (Standard) can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Olsalazine-d6 | Olsalazine-d6 is the deuterium labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Olsalazine-13C6 | Olsalazine-13C6 is the 13C labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Olsalazine-d3,15N | Olsalazine-d3,15N is 15N and deuterated labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Brown WA, et al. 5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig Dis Sci. 2000 Aug;45(8):1578-84. [Content Brief]
- [2]. Thapa D, et al. Cannabidiol Enhances the Therapeutic Efficacy of Olsalazine and Cyclosporine in a Murine Model of Colitis. Int J Mol Sci. 2025 Aug 16;26(16):7913. [Content Brief]
- [3]. Niu Y, et al. Olsalazine Sodium Increases Renal Urate Excretion by Modulating Urate Transporters in Hyperuricemic Animals. Biol Pharm Bull. 2020 Nov 1;43(11):1653-1659. [Content Brief]
- [4]. Itoh S, et al. Olsalazine inhibits cell proliferation and DNA methylation in canine lymphoid tumor cell lines. Pol J Vet Sci. 2021 Dec;24(4):515-523. [Content Brief]
